Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Dombi

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2017
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with VandetanibIra L Kraft, Srivandana Akshintala, Yuelin Zhu, et al.
Pediatric Blood & Cancer|April 23, 2014
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Dusica Babovic-Vuksanovic, Eva Dombi, et al.
Clinical Trials (London, England)|October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1Liny John, Gurbani Singh, Eva Dombi, et al.
Neuro-Oncology|February 7, 2014
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Eva Dombi, Andrea Gillespie, et al.
The Journal of Clinical Investigation|December 11, 2012
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsWalter J Jessen, Shyra J Miller, Edwin Jousma, et al.
American Journal of Human Genetics|February 27, 2019
Pharmacodynamic Study of Miransertib in Individuals with Proteus SyndromeKim M Keppler-Noreuil, Julie C Sapp, Marjorie J Lindhurst, et al.
Lancet (London, England)|June 5, 2025
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 studyAlice P Chen, Geraldine O'Sullivan Coyne, Pamela L Wolters, et al.
Neuro-Oncology|February 6, 2019
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromasAlexander Pemov, Nancy F Hansen, Sivasish Sindiri, et al.
Neurology|November 20, 2013
Recommendations for imaging tumor response in neurofibromatosis clinical trialsEva Dombi, Simone L Ardern-Holmes, Dusica Babovic-Vuksanovic, et al.
Neuro-Oncology|April 28, 2023
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromasAndrea M Gross, Eva Dombi, Pamela L Wolters, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2017
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with VandetanibIra L Kraft, Srivandana Akshintala, Yuelin Zhu, et al.
Pediatric Blood & Cancer|April 23, 2014
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Dusica Babovic-Vuksanovic, Eva Dombi, et al.
Clinical Trials (London, England)|October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1Liny John, Gurbani Singh, Eva Dombi, et al.
Neuro-Oncology|February 7, 2014
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Eva Dombi, Andrea Gillespie, et al.
The Journal of Clinical Investigation|December 11, 2012
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsWalter J Jessen, Shyra J Miller, Edwin Jousma, et al.
American Journal of Human Genetics|February 27, 2019
Pharmacodynamic Study of Miransertib in Individuals with Proteus SyndromeKim M Keppler-Noreuil, Julie C Sapp, Marjorie J Lindhurst, et al.
Lancet (London, England)|June 5, 2025
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 studyAlice P Chen, Geraldine O'Sullivan Coyne, Pamela L Wolters, et al.
Neuro-Oncology|February 6, 2019
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromasAlexander Pemov, Nancy F Hansen, Sivasish Sindiri, et al.
Neurology|November 20, 2013
Recommendations for imaging tumor response in neurofibromatosis clinical trialsEva Dombi, Simone L Ardern-Holmes, Dusica Babovic-Vuksanovic, et al.
Neuro-Oncology|April 28, 2023
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromasAndrea M Gross, Eva Dombi, Pamela L Wolters, et al.
Pageof 10